Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis
Ruxolitinib Combo Regimens Emerging in Myelofibrosis
JAK Inhibition Continues to Push Progress in Myelofibrosis
Related Videos
Dr. Michaelis on Fedratinib in Myelofibrosis Treatment
Unmet Needs and Future Directions in Treating MPNs
Other Pathways Studied for MF
News >

Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

Published: Friday, Dec 16, 2016

Lynda Foltz, MD

Lynda Foltz, MD

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial, a review of data from an expanded access program showed.1

 
1. Foltz L, Paulmbo GA, Martino B, et al. Safety and efficacu of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm expanded-access study in patients with myelofibrosis. Presented at: 58th ASH Annual Meeting and Exposition; December 2-6, 2016; San Diego, CA. Abstract 3107.

... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x